# US 8,541,560 B2 · Polypeptides comprising Fas activation and NKG2D-ligand domains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,560 B2
- Document ID: US8541560B2
- Status: Granted
- Kind: B2
- Application number: 12/826,544
- Filed: 2010-06-29
- Published: 2010-11-11
- Granted: 2013-09-24
- Earliest claimed: 2006-11-28
- Assignees: Thomas E. Wagner
- Applicants: Thomas E. Wagner; Yanzhang Wei
- Inventors: Thomas E. Wagner; Yanzhang Wei
- Web page: https://patentgrep.com/patent/US8541560B2

## CPC

- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- A61P 35/00: Antineoplastic agents
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is drawn to fusion proteins comprising (a) a ligand for an NK receptor and (b) a Fas activation domain, and to nucleic acids encoding such fusion proteins. The invention also includes methods of making and using such proteins and nucleic acids, including their use in preventing or treating cancer.

## Claims

### Claim 1

A polynucleotide encoding the polypeptide comprising (i) a ligand for a stimulatory Natural Killer (NK) receptor and (ii) an intracytoplasmic death domain (DD), wherein the polynucleotide comprising nucleotides 7 to 1134 of SEQ ID NO: 4.

### Claim 2 (depends on 1)

A polynucleotide comprising the polynucleotide of claim 1, operatively linked to a promoter.

### Claim 3 (depends on 2)

The polynucleotide of claim 2, wherein said promoter is activated in cancer.

### Claim 4 (depends on 1)

A method of promoting NK-mediated killing of a target cell comprising delivering the polynucleotide of claim 1, to said target cell.

### Claim 5 (depends on 1)

A method of treating cancer, comprising administering the polynucleotide of claim 1, to a cancer cell.

### Claim 6 (depends on 5)

The method of claim 5, wherein said polynucleotide is administered directly to a tumor.

### Claim 7 (depends on 6)

The method of claim 6, wherein said polynucleotide is administered via an adenovirus.

### Claim 8 (depends on 1)

A composition comprising the polynucleotide of claim 1, and a pharmaceutically acceptable excipient.

### Claim 9 (depends on 1)

A viral particle, comprising the polynucleotide of claim 1.